Table 3.
Differences between parameters at baseline and after three months in responders and non-responders.
| Responder Median (75–25 Percentiles) |
Non-Responder Median (75–25 Percentiles) |
|||||
|---|---|---|---|---|---|---|
| V1 | V2 | p 1 | V1 | V2 | p 1 | |
|
Headaches frequency
(days/month) |
22.00 (30–14) | 5.00 (6–3) | <0.001 *** | 30.00 (30–15) | 20.00 (30–12) | 0.003 ** |
| MIDAS | 96.00 (135–70) | 8.00 (39–2) | <0.001 *** | 99.00 (15278) | 38.00 (60–26) | <0.001 *** |
|
ASC-12
(raw data) |
6.00 (9–3) | 1.50 (5–0) | <0.001 *** | 5.00 (12–2) | 6.00 (9–1) | 0.241 |
|
ASC-12
(clinical score) |
Moderate (3–1) | Absent (1–0) | <0.001 *** | Mild (3–0) | Mild(3–0) | 0.476 |
|
GAD7
(raw data) |
8.00 (12–6) | 6.00 (7–3) | 0.001 ** | 10.00 (13–5) | 7.00 (10–6) | 0.130 |
|
GAD7
(clinical score) |
Mild (2–1) | Mild (1–0) | 0.002 ** | Moderate (2–1) | Mild (2–1) | 0.034 * |
|
PHQ9
(raw data) |
7.00 (12–5) | 4.00 (7–2) | <0.001 *** | 10.00 (14–6) | 8.00 (13–6) | 0.184 |
|
PHQ9
(clinical score) |
Mild (2–1) | Absent (1–0) | <0.001 *** | Mild-Moderate (2–1) | Mild (2–1) | 0.414 |
| FSS | 43.50 (57–26) | 29.00 (40–17) | 0.001 ** | 54.00 (61–44) | 42.00 (55–39) | 0.109 |
1 Wilcoxon test; MIDAS: Migraine Disability Assessment Scale; FSS: Fatigue Severity Scale; ASC-12: Allodynia Symptom Checklist 12; GAD7: Generalized Anxiety Disorder 7; PHQ9: Patient Health Questionnaire 9; Clinical score:. Severe = 3; Moderate = 2; Mild = 1; Moderate-Mild = 1.5; Absent = 0 (* p < 0.5; ** p < 0.01; *** p < 0.001).